KamiJ.MaddocksMD

Hematology • Columbus, OH

Assistant Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Maddocks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maddocks' full profile

Already have an account?

Office
460 W 10th Ave
Columbus, OH 43210
Phone+1 614-293-8619

Fax+1 614-293-6420

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
University of South Dakota, Sanford School of MedicineClass of 2005

Certifications & Licensure

OH State Medical License 2008 - 2026
MN State Medical License 2006 - 2008
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2011 Dec 07
Active, not recruiting
Phase 1
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Start of enrollment: 2012 Jan 01
Completed
Phase 1
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Start of enrollment: 2012 May 21
Active, not recruiting
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Start of enrollment: 2014 Jul 21
Completed
Phase 1
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2017 Jan 12
Completed
Phase 1
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Start of enrollment: 2017 Feb 14
Active, not recruiting
Phase 1, Phase 2
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas Start of enrollment: 2017 Feb 06
Completed
Phase 1
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Start of enrollment: 2018 Sep 11
Active, not recruiting
Phase 2
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2019 Jan 02
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

157 citations
NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun
Journal of the National Comprehensive Cancer Network. 2018-03-01
610 citations
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski
Blood. 2013-10-10
134 citations
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski
Blood. 2015-07-02

Journal Articles

Update on Mantle Cell Lymphoma
Kami Maddocks, MD, Blood

Abstracts/Posters

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as...
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc_Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B_Cell Non...
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Restoring Functional Deficits in Older Adults with Hematologic Malignancy
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Targeting Hypersumoylation in Mantle Cell Lymphoma
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patie...
2019 ASCO Annual Meeting - 6/1/2019
Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

The Ohio State Kicks off Blood Battle Against University of MichiganOctober 22nd, 2024
Comorbidities and Role of R-CHOP in DLBCLFebruary 7th, 2020
Potential Ibrutinib Resistance Mechanisms Identified in CLLMarch 20th, 2015